Howe & Rusling’s GoodRx Holdings GDRX Stock Holding History

Howe & Rusling’s Portfolio GDRX Stock Details GDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-150	Closed	-$1K	–	1107
2022 Q2	$1K	Buy	+150	New	+$1.67K	﹤0.01%	947

Other funds holding GDRX

FPM

Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSCM

Light Street Capital Management Palo Alto, California $534M AUM 59.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SLG

Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PTC

Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCMX

Technology Crossover Management X Menlo Park, California $781M AUM 18.39% 1-Year Est. Return

Howe & Rusling's GDRX Position: Q3 2022 in Review

Howe & Rusling sold out of GoodRx Holdings (GDRX) in Q3 2022, closing a stake of 150 shares — an estimated $1K sold.

Howe & Rusling first reported a position in GDRX in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 180 funds tracked by Wall St. Rank hold GDRX as of Q3 2022.

Howe & Rusling reported no remaining GoodRx Holdings position as of Q3 2022 after selling out during the quarter.
Howe & Rusling sold 150 GoodRx Holdings shares in Q3 2022, an estimated $1K.
Howe & Rusling first reported a position in GoodRx Holdings in Q2 2022 and held it in 1 quarter.
Howe & Rusling's GoodRx Holdings position peaked at $1K in Q2 2022.
180 funds tracked by Wall St. Rank held GoodRx Holdings as of Q3 2022.

Based on Howe & Rusling's 13F filing for Q3 2022, filed 14 Nov 2022.